Lumos Diagnostics (ASX: LDX) — Company Overview, News & Financial Data
Lumos Diagnostics develops rapid diagnostic tests and its Lumos Platform for various diseases, enhancing healthcare accessibility.
Lumos Diagnostics
Lumos Diagnostics is a developer, manufacturer, and distributor of point-of-care diagnostic technologies and contract development services. The company specializes in rapid diagnostic test solutions designed to deliver actionable clinical information in real time at the point of care. Its product portfolio includes rapid point-of-care diagnostic tests, such as fingerstick blood tests that assist healthcare professionals in differentiating between bacterial and non-bacterial acute respiratory infections. In addition to proprietary products, the company provides customized assay development, digital reader technology development, cloud connectivity integration, contract manufacturing, and regulatory compliance services for commercial partners across global healthcare markets.
Snapshot
Operations
Products and/or services of Lumos Diagnostics
- Point-of-Care Diagnostic Products: Rapid point-of-care diagnostic test solutions including fingerstick blood tests designed to differentiate between bacterial and non-bacterial respiratory infections, distributed through healthcare networks across key medical markets in Australia and the United States.
- Customized Assay Development Services: Comprehensive contract development solutions for point-of-care diagnostic products, covering initial concept evaluation, biomarker feasibility, and the custom engineering of lateral flow test assays tailored to specific partner specifications and clinical applications.
- Digital Reader Platform Development: Proprietary optical and electronic reader technologies that provide custom hardware and software integration to capture, read, and process qualitative or quantitative point-of-care diagnostic assay results for clinical and commercial partners.
- App and Cloud Connectivity Infrastructure: Digital healthcare software services providing mobile applications and cloud platform integration to support secure data management, real-time reporting, and seamless transmission of point-of-care diagnostic results into healthcare data networks.
- Validation and Commercial Contract Manufacturing: Scalable manufacturing and production transfer services for point-of-care diagnostic test strips and reader devices, offering clinical batch validation, assembly, packaging, and high-volume commercial production for client diagnostic products.
- Medical, Quality, and Regulatory Support Services: Integrated regulatory and clinical advisory services supporting all stages of diagnostic product commercialization, including quality assurance systems, clinical validation studies, and regulatory submission management across global healthcare markets.
Lumos Diagnostics executive team
- Douglas WardCEO, MD & Director
- Barrie LambertChief Financial Officer
- Anthony FavaloroVice President of Quality & Operations
- Sacha DopheideChief Technology Officer
- Sarah GlubkaVice President of Human Resources
- Paul KaseChief Commercial Officer
- Tracy WeimarCompany Secretary
- Annie BellVice President of Medical Affairs
- Amelia StephensGlobal Marketing and Awareness Consultant
Latest news about Lumos Diagnostics
Lumos Diagnostics secures rollout across 30 US sites
AustraliaLumos secures Micro-Pak manufacturing deal and order
AustraliaLumos Diagnostics secures US$1.3M FebriDx order
AustraliaLumos Diagnostics secures FDA milestone, $25M funding
AustraliaLumos Diagnostics secures Baltic distribution for FebriDx
Australia
Recent announcements
What Lumos Diagnostics (LDX) has told the market, newest first.
- Final Director's Interest Notice - LM
- Initial Director's Interest Notice - AS
- Notice of Annual General Meeting and Proxy Form
- Lumos Diagnostics Board Changes
- Notification of cessation of securities - LDX
- Application for quotation of securities - LDX
- Change of Director's Interest Notice - CR
Key financials
Reported results for Lumos Diagnostics, in USD.
- Market cap
- 57.3M
- Revenue (TTM)
- 13.2M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- -37.5%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 13.5M | -14.4M | -5.1M | |
| 12.5M | -7.8M | -7.2M | |
| 11.1M | -7.1M | -8.6M | |
| 10.5M | -6.6M | -9M |